263400-90-4

Basic information

• Product Name: 2-Chloro-N-(3-nitrophenyl)-4-pyridinecarboxamide
• Synonyms: 2-Chloro-N-(3-nitrophenyl)isonicotinamide; 4-pyridinecarboxamide, 2-chloro-N-(3-nitrophenyl)-
• CAS NO: 263400-90-4
• Molecular Formula: C₁₂H₈ClN₃O₃
• Molecular Weight: 0
• Mol File: 263400-90-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 371.995°C at 760 mmHg
• Flash Point: 178.776°C
• Appearance: /
• Density: 1.498g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.684
• CAS DataBase Reference: 2-Chloro-N-(3-nitrophenyl)-4-pyridinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-N-(3-nitrophenyl)-4-pyridinecarboxamide(263400-90-4)
• EPA Substance Registry System: 2-Chloro-N-(3-nitrophenyl)-4-pyridinecarboxamide(263400-90-4)

Safety Data

• Hazardous Substances Data: 263400-90-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H8ClN3O3/c13-11-6-8(4-5-14-11)12(17)15-9-2-1-3-10(7-9)16(18)19/h1-7H,(H,15,17)

Upstream product

• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 99-09-2 3-nitro-aniline 

Relevant articles and documents

DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

Substituted anilino-quinazoline (or quinoline) compounds and use thereof

The invention concerns amide derivatives of Formula (I), wherein: G is N or CH; R1is a group such as hydroxy, halo, trifluoromethyl, C1-6alkyl and C1-6alkoxy; each of R2and R3is hydrogen, halo, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4is a group such as hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy and C3-7cycloalkyl, or R4is of the Formula (IC): —K—J, wherein J is aryl, heteroaryl or heterocyclyl and K is a bond or a group such as oxy and imino, R5is a group such as hydrogen, halo and trifluoromethyl: m is 1-3 and q is 0-4; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.